INTRODUCTION
Psoriasis is a chronic inflammatory disease mediated by immune response, characterized by erythematous scaly lesions. It does not present predilection for sex and can emerge at any age. Its development is influenced by genetic factors, immune response alteration and environmental stimulus. 1 Proinflammatory cytokines are released, such as TNF-alpha, IL-12 and 23. World prevalence is estimated to be 3%, but there are no studies on this in Brazil. 20-30% of the patients suffer from the severe form of the disease; of these, 10% of cases are associated with arthritis. The disease is considered extensive when over 10% of body surface area (BSA) is affected; thus, it has indication for systemic therapy because of potential complications. Systemic capillary leak syndrome is the complication that more frequently results in death, and often occurs from pustular and erythrodermic forms, the most unstable ones. 1, 2 In systemic capillary leak syndrome the endothelium is deeply involved with increased VEGF and ICAM-1, resulting in thermoregulation disorder, dehydration, tachycardia, pericardial and pulmonary effusion, respiratory distress in adults and even death. This literature review assessed the relevance of these molecules and their links with complications. More studies should be conducted for better understanding the physiopathology, how exactly these molecules act in psoriasis and new possible therapies that decrease an unfortunate outcome. 4 When studying the age when the disease first started to spread, it is possible to observe that it has a bimodal behavior, with a peak (75% of the cases) before 40 and another around 55-60 years old. An earlier peak is intimately related to positive family history. It requires quick and effective treatment. Erythrodermic psoriasis, on the other hand, can be described when more than 80% of body surface is affected by erythema, scaling, edema with or without exudate, alopecia and nail dystrophy. 9 It is followed by pruritus and interruption of daily routine, either due to indisposition or discriminatory behavior towards the patient. Its installation can be slower than the pustular form and this fact interfers directly in the organism capacity of adaptation to these changes. The more sudden it starts, the less time the organism has to adapt to hydroelectrolitic and protein losses, and it may present fever, hypotension, thermoregulatory disorder and even shock, all deriving from endothelial injuries. Thus, this condition leads to the most alarming complication of all -the systemic capillary leak syndrome, described bellow.
EPIDEMIOLOGY

GENETICS
SYSTEMIC CAPILLARY LEAK SYNDROME
Also known as leak syndrome, it is rare and caused by the increase of capillary permeability. This results in accumulation of fluids and protein in the interstitial or extravascular sites, followed by a subsequent hypovolemic shock. 10 It is a severe and potentially fatal condition if not managed correctly. It is more prevalent be-
How relevant are vascular endothelial growth factor and intercellular adhesion molecule in the systemic...Bressan AL, Pereira D, Medeiros PM, Carneiro S, Azulay-Abulafia L
tween the fourth and fifth decades of life and both men and women are affected.
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There are three types of this syndrome: idiopathic, drug-induced and associated to skin diseases, commonly erythrodermic and pustular psoriasis. [12] [13] [14] Mechanism that helps increase capillary permeability are not yet clear, but many hypothesis were studied:
· IL-2 and 6, IFN−γ and TNF-α would cause endothelial injury; · Leukotriene B4 acts over capillary permeability, since its accumulation was detected in vitro 15 ;
· Endothelial cells apoptosis caused by increase of nitric oxide, generated in the serum of patients with the syndrome; · Elevation of VEGF in patients that present large skin injuries, inducing even more leak through microvasculature (general pustular psoriasis is followed by high levels of VEGF, produced by psoriatic plaques). 16 The syndrome has three phases but, when related to skin lesions, the first phase -prodromal phase -is absent. come, anticipating treatment and avoiding evolution to endothelial damage. As they have more evidence of being involved in psoriasis pathogenesis, both will be better discussed next, considering VEGF the primary angiogenic factor in this process. 20 Among treatments, the following have been reported: systemic treatment with corticosteroids, when the cause for the dermatitis is unknown or, when it is psoriasis, but associated with respiratory distress syndrome in adults or pulmonary edema. Cyclosporine takes place when the etiology is unstable psoriasis (erythrodermic or pustular), without respiratory distress. 21 Some options are under study, such as medications that inhibit VEGF or its pathways.
VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF)
It is a glycoprotein released in the vascular wall by the endothelium and by straight muscles cells, with varied consequences to the endothelium. 22 Among its functions, it makes venules hyper permeable to macromolecules, creates accumulation of cytoplasmic calcium, cell division and migration, and induces angiogenesis. 23 It has two high-affinity receptors in the vascular endothelium, both transmembrane proteins. 24 Where there is overexpression of VEGF, the expression of receptors also increases in adjacent endothelial cells. One of those places is the dermis of psoriasis patients. There are extensive evidences indicating that vascular hyperpermeability controls, conducts or even precedes angiogenesis. VEGF acts by permeabilizing many different vascular beds, such as skin, mesentery, and diaphragm. This substance has its expression increased during important non-neoplastic diseases, characterized by angiogenesis.
In these cases, it seems that capillaries are hyperpermeable as in psoriasis, rheumatoid arthritis and wound healing process. 25 This manifestation occurs through TGF-α (transformation growth factor) and EGF (epidermal growth factor) acting over keratinocytes and macrophages, which begin overexpressing VEGF, with its plasmatic concentration related to the extent of the skin injuries. Therefore, over expression of VEGF and its receptors, in addition to extravascular deposition of fibrin, conduct angiogenesis in psoriasis and responds accordingly to the lesions status. 20 As reported before, in pustular psoriasis, VEGF is in high levels and produced by the plaques. Numerous antiangiogenic substances have been reported by literature, such as corticosteroid, thalidomide and tumor necrosis factor-alpha inhibitors.
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INTERCELLULAR ADHESION MOLECULE (ICAM-1)
It is a member of an immunoglobulin superfamily, necessary for leucocytes adherence to capillary endothelium. 27 It has an important role in recruiting and retaining proinflammatory cells.
Leucocytes activation, circulation and migration to inflammatory sites depend on this molecule. TNF-α, together with interleukin 1 and reactive C protein, is the main responsible for expressing this molecule to endothelium, macrophages and lymphocytes, via protein kinase C activation. 28 When TNF-α is presented in high levels, ICAM-1 begins allowing that lymphocytes link to endothelium and migrate to the tissue, leading to microvascular hyperpermeability.
These events allow the transfer of solutes to peripheral tissues. 29 As a result, there is an alteration in albumin transport during inflammatory process and its journey is influenced by TNF-α and ICAM-1.
CONCLUSION
Studies that evaluate skin and blood levels of VEGF and ICAM-1 in psoriasis patients are necessary in order to have their relevance recognized, correlating the levels of these substances with the disease's importance and subtypes and, possibly, influencing new treatments. q
